-

05:51:44 PM

VYNE Stock News

VYNE - VYNE Therapeutics Inc

06/17/22 8:00 AM

Nasdaq : VYNE

clinical trial

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of

RHEA-AI

neutral

05/18/22 8:00 AM

Nasdaq : VYNE

conferences

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : VYNE

earnings

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBET TM BET inhibitor platform on May 17 th BRIDGEWATER, N.J., May 12, 2022

RHEA-AI

neutral

05/10/22 8:00 AM

Nasdaq : VYNE

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of

RHEA-AI

neutral

05/06/22 8:00 AM

Nasdaq : VYNE

conferences

VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David

RHEA-AI

neutral

04/07/22 8:00 AM

Nasdaq : VYNE

clinical trial

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. (Nasdaq:

RHEA-AI

neutral

03/30/22 8:00 AM

Nasdaq : VYNE

clinical trial

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis

VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses VYN201 also demonstrated numerically superior results at 1mg/kg and 10mg/kg doses compared to leading injectable steroid, dexamethasone, in inhibiting inflammation in

RHEA-AI

neutral

03/17/22 8:00 AM

Nasdaq : VYNE

earnings

VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the

RHEA-AI

neutral

03/07/22 7:00 AM

Nasdaq : VYNE

clinical trial

VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo

VYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflammatory biomarkers involved in the pathogenesis of vitiligo, an immune-modulated skin disorder. VYN201 0.1% and 1% demonstrated upregulaton of the WNT signalling pathway, recognized as

RHEA-AI

neutral

03/03/22 8:00 AM

Nasdaq : VYNE

conferences

VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David

RHEA-AI

neutral

1 2 3 4 5 6 Next